Chlorthalidone

also known as CTD · chlorthalidone (Thalitone) · HIGROTON 50 · Hygroton (brand name for chlorthalidone)

Developed for: hypertensive disorder · essential hypertension · chronic kidney disease · heart failure · obstructive sleep apnea syndrome · end stage renal failure · idiopathic hypercalciuria · nephrolithiasis, calcium oxalate
+5 more
· resistant hypertension · secondary hypertension · urolithiasis · arteriosclerosis disorder · metabolic syndrome X
Investigated by: Takeda · National Heart, Lung, and Blood Institute (NHLBI) · EMS · Hospital de Clinicas de Porto Alegre · Yuhan Corporation · VA Office of Research and Development
+38 more
· AJU Pharm Co., Ltd. · Creighton University · Hanmi Pharmaceutical Company Limited · Indiana University · National Institute on Aging (NIA) · University of California, San Francisco · Addpharma Inc. · Dialysis Clinic, Inc. · Erasmus Medical Center · Eurofarma Laboratorios S.A. · Farma de Colombia SA · Financiadora de Estudos e Projetos · Hanlim Pharm. Co., Ltd. · Hospital General de México Dr. Eduardo Liceaga · Hospital Israelita Albert Einstein · Icahn School of Medicine at Mount Sinai · Indiana Institute for Medical Research · Instituto de Cardiologia do Rio Grande do Sul · Jessa Hospital · Kyungdong Pharmaceutical Co., Ltd. · Laboratorios Silanes S.A. de C.V. · Libbs Farmacêutica LTDA · Michael E. DeBakey VA Medical Center · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute of General Medical Sciences (NIGMS) · National University of Ireland, Galway, Ireland · Parc de Salut Mar · Roche Diagnostics GmbH · Seoul National University Bundang Hospital · University of Alabama at Birmingham · University of Alberta · University of Florida · University of Minnesota · University of Rochester · VA New York Harbor Healthcare System · VA Salt Lake City Health Care System · Virginia Commonwealth University · Vrije Universiteit Brussel

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	HYGROTON	—	1960-04-07	fda.gov ↗

Trials 57

today

US approved 1960

NCT07645300 · Ph 2 NCT07225764 · Ph 4 NCT02483936 · Ph 3 NCT02493322 · Ph 3 NCT06348576 · Ph 3 NCT06041529 · Ph 4 NCT05920005 · Ph 3 NCT05915286 · Ph 4 NCT05171686 · Ph 4 NCT04927299 · Ph 3 NCT07116863 · Ph 3 NCT05411991 · Ph 4 NCT05370599 · Ph 2 NCT05222191 · Ph 2 NCT05077475 · Ph 1 NCT05077462 · Ph 1 NCT04757532 · Ph 1 NCT04192110 · Ph 4 NCT04330300 · Ph 4 NCT03928145 · Ph 3 NCT03325114 · Ph 2 NCT03923933 · Ph 2 NCT03666351 · Ph 4 NCT03662620 · Ph 1 NCT02521233 · Ph 3 NCT02521246 · Ph 3 NCT02841280 · Ph 2 NCT02620163 · Ph 3 NCT03226340 · Ph 4 NCT02916602 · Ph 3 NCT02357004 · not/applicable NCT01896661 · Ph 3 NCT02896621 · Ph 3 NCT02152969 · Ph 1 NCT02100462 · Ph 4 NCT02711670 · not/applicable NCT02030314 · Ph 4 NCT01850160 · Ph 3 NCT01822860 · Ph 4 NCT02644395 · Ph 3 NCT01750294 · Ph 4 NCT01456169 · Ph 3 NCT01191450 · Ph 3 NCT01309828 · Ph 3 NCT01203852 · Ph 4 NCT00970931 · Ph 3 NCT01033071 · Ph 3 NCT00996281 · Ph 3 NCT00846365 · Ph 3 NCT00818883 · Ph 3 NCT00847626 · Ph 3 NCT00000542 · Ph 3 NCT00000525 · Ph 3 NCT00000522 · Ph 2 NCT00000514 · Ph 3 NCT00000513 · Ph 3 NCT00000499 · Ph 2

1959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT05077475	Sep 2021 → Apr 2022	hypertensive disorder	AJU Pharm Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT05077462	Sep 2021 → Apr 2022	hypertensive disorder	AJU Pharm Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT04757532	Dec 2020 → Mar 2021	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03662620	Oct → Dec 2018	hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT02152969	May → Aug 2014	hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 28 trials · 2 met primary
Phase 2	NCT07645300	Oct 2026 → Mar 2032 expected	chronic kidney disease	VA Office of Research and Development	Not yet recruiting	No outcome recorded
Phase 2	NCT05370599	Apr 2022 → Jan 2026	hypertensive disorder	University of California, San Francisco	Terminated	No outcome recorded Stop: Business
Phase 2	NCT05222191	Feb 2022 → Dec 2023	chronic kidney disease, hypertensive disorder	Indiana Institute for Medical Research	Unknown	No outcome recorded
Phase 2	NCT03325114	Jun 2019 → Jun 2020	idiopathic hypercalciuria, type 1 diabetes mellitus	University of Rochester	Terminated	No outcome recorded
Phase 2	NCT03923933	Jun → Oct 2019	chronic kidney disease	Hospital General de México Dr. Eduardo Liceaga	Completed	Met primary
Phase 2	NCT02841280	Jul 2016 → Apr 2021	chronic kidney disease, hypertensive disorder	Indiana University	Completed	Met primary
Phase 2	NCT00000522	Aug 1985 → May 1994	heart disorder, hypertensive disorder	University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00000499	Sep 1980 → May 1983	heart disorder, hypertensive disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 328 trials · 10 met primary · 2 missed
Phase 3	NCT06348576	May 2024 → Feb 2025	essential hypertension	Addpharma Inc.	Unknown	Met primary
Phase 3	NCT05920005	Aug 2023 → Mar 2025	hypertensive disorder	Hospital Israelita Albert Einstein	Completed	Met primary
Phase 3	NCT04927299	Jun 2022 → Aug 2023	essential hypertension	Laboratorios Silanes S.A. de C.V.	Completed	No outcome recorded
Phase 3	NCT07116863	Jun 2022 → Jun 2024	essential hypertension	Kyungdong Pharmaceutical Co., Ltd.	Completed	Met primary
Phase 3	NCT03928145	Nov 2019 → Jul 2021	essential hypertension	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
Phase 3	NCT02521233	Nov 2016 → May 2017	essential hypertension	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT02521246	Nov 2016 → May 2017	essential hypertension	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT02620163	Dec 2015 → Dec 2016	essential hypertension	Yuhan Corporation	Completed	No outcome recorded
Phase 3	NCT02916602	Apr 2015 → Sep 2016	hypertensive disorder	Hanmi Pharmaceutical Company Limited	Completed	Met primary
Phase 3	NCT02896621	Dec 2014 → Feb 2016	hypertensive disorder, obstructive sleep apnea syndrome	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 3	NCT01896661	Dec 2014 → Dec 2015	hypertensive disorder, obstructive sleep apnea syndrome	Hospital de Clinicas de Porto Alegre	Completed	Missed primary
Phase 3	NCT01850160	Apr 2013 → Mar 2015	hypertensive disorder	Farma de Colombia SA	Completed	No outcome recorded
Phase 3	NCT02644395	Jan 2013 → Dec 2015	secondary hypertension	Erasmus Medical Center	Completed	No outcome recorded
Phase 3	NCT01456169	Oct 2011 → Dec 2012	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT01191450	Aug 2011 → Aug 2013	hypertensive disorder	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT01309828	Mar 2011 → Oct 2012	—	Takeda	Completed	No outcome recorded
Phase 3	NCT00970931	Jul 2010 → Sep 2014	hypertensive disorder	Hospital de Clinicas de Porto Alegre	Completed	Met primary
Phase 3	NCT01033071	Jan → Oct 2010	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT00996281	Oct 2009 → Nov 2011	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00846365	Mar 2009 → Jun 2010	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT00818883	Feb → Nov 2009	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT00847626	Jan 2009 → May 2010	hypertensive disorder	Takeda	Completed	Met primary
Phase 3	NCT00000542	Aug 1993 → Mar 2002	coronary artery disorder, diabetes mellitus, heart failure, hyperlipidemia +3	National Heart, Lung, and Blood Institute (NHLBI)	Completed	Missed primary
Phase 3	NCT00000525	Jul 1986 → Sep 1989	cardiac arrest, hypertensive disorder, sudden arrhythmia death syndrome	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00000514	Jun 1984 → Oct 1996	cerebrovascular disorder, heart disorder, hypertensive disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00000513	Apr 1984 → Nov 1994	heart disorder, hypertensive disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT02483936	? → Jun 2025	essential hypertension	EMS	Withdrawn	No outcome recorded
Phase 3	NCT02493322	? → Jun 2025	essential hypertension	EMS	Withdrawn	No outcome recorded

Phase 414 trials · 1 met primary · 1 missed
Phase 4	NCT07225764	Oct 2025 → Jun 2027 expected	nephrolithiasis, calcium oxalate	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 4	NCT06041529	Oct 2023 → Feb 2026 overdue	essential hypertension	Yuhan Corporation	Active not recruiting	No outcome recorded
Phase 4	NCT05915286	May 2023 → Feb 2025	end stage renal failure	University of Alberta	Terminated	No outcome recorded
Phase 4	NCT05171686	Feb 2023 → Oct 2025	chronic kidney disease, hypertensive disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT05411991	Jun 2022 → Jul 2024	heart failure	Vrije Universiteit Brussel	Completed	Missed primary
Phase 4	NCT04192110	Aug 2020	chronic kidney disease	VA Office of Research and Development	Withdrawn	No outcome recorded
Phase 4	NCT04330300	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded Stop: Business
Phase 4	NCT03666351	Oct 2018 → Jul 2022	aortic valve insufficiency, aortic valve stenosis, hypertensive disorder	Hanmi Pharmaceutical Company Limited	Completed	Met primary
Phase 4	NCT03226340	Dec 2015 → Mar 2018	essential hypertension	Seoul National University Bundang Hospital	Unknown	No outcome recorded
Phase 4	NCT02100462	Mar 2014 → Dec 2016	hypertensive disorder	Creighton University	Unknown	No outcome recorded
Phase 4	NCT02030314	Jul 2013 → Apr 2017	resistant hypertension	Virginia Commonwealth University	Withdrawn	No outcome recorded
Phase 4	NCT01822860	Mar 2013 → Feb 2015	hypertensive disorder	Creighton University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01750294	Aug 2012 → Aug 2013	chronic kidney disease, hypertensive disorder	Indiana University	Completed	No outcome recorded
Phase 4	NCT01203852	Aug 2010 → Apr 2014	hypertensive disorder	University of Florida	Completed	No outcome recorded

Phase not applicable2 trials
—	NCT02357004	Feb 2015 → Jan 2020	hypertensive disorder	University of Alabama at Birmingham	Withdrawn	No outcome recorded
—	NCT02711670	Feb 2014 → Jun 2017	urolithiasis	VA New York Harbor Healthcare System	Completed	No outcome recorded
Comparator or background therapy24 trials
Phase 0	NCT06287580 Comparator	Aug 2024 → Feb 2026	essential hypertension	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1	NCT05090449 Comparator	May 2019 → Apr 2020	—	Laboratorios Silanes S.A. de C.V.	Completed	No outcome recorded
Phase 1	NCT02496910 Comparator	Jun → Sep 2015	hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT01806363 Comparator	Nov 2012 → Jun 2013	hypertensive disorder	HanAll BioPharma Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT07238400 Comparator	Mar 2026 → Mar 2029 expected	hypertensive disorder	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 2	NCT06111885 Comparator	Oct 2024 → Jun 2027 expected	urolithiasis	Insel Gruppe AG, University Hospital Bern	Recruiting	No outcome recorded
Phase 2	NCT02236520 Comparator	Sep 2014 → May 2018	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 3	NCT02185417 Comparator	Jun 2016 → Oct 2022	hypertensive disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 3	NCT00971165 Comparator	Jul 2010 → Sep 2014	hypertensive disorder	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 3	NCT00591773 Comparator	Sep 2007 → Mar 2009	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT00696384 Background	Jun 2007 → Apr 2009	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT00695955 Background	Jun 2007 → May 2010	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00241839 Comparator	Aug 2005 → May 2011	heart disorder, hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 3	NCT00000620 Background	Sep 1999 → Jun 2009	atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1	National Heart, Lung, and Blood Institute (NHLBI)	Completed	Missed primary
Phase 4	NCT05593055 Comparator	Aug 2023 → Apr 2027 expected	hypertensive disorder	Brigham and Women's Hospital	Recruiting	No outcome recorded
Phase 4	NCT05275907 Comparator	Jul 2022 → Oct 2023	hypertensive disorder, impaired renal function disease	Northwestern University	Withdrawn	No outcome recorded
Phase 4	NCT04519164 Comparator	Dec 2020 → Sep 2025	hypertensive disorder, metabolic syndrome X	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT01748123 Comparator	Aug 2016 → Jun 2017	hypertensive disorder	Johns Hopkins University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01368536 Comparator	May 2011 → Feb 2012	hypertensive disorder, type 2 diabetes mellitus	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT00353652 Comparator	Jan 2005 → Jan 2013	hypertensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
—	NCT02665117 Comparator	Jan 2015 → Nov 2022	hypertensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
—	NCT03560804 Comparator	Nov 2014 → Sep 2017	arteriosclerosis disorder	AHEPA University Hospital	Completed	No outcome recorded
—	NCT02121041 Comparator	May 2014 → Sep 2015	hypertensive disorder	Anthony J Viera, MD, MPH	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 10

Date	Issuer	Release
2025-06-13	Hanmi Pharmaceutical Company Limited	Regulatory “고혈압 1차 치료의 새로운 길”…한미약품 ‘아모프렐’ 출격 준비 hanmi.co.kr ↗ 한미약품은 최근 식품의약품안전처로부터 저용량 3제 항고혈압제 ‘아모프렐정’의 품목허가를 획득하고 출시를 위한 채비에 들어갔다고 13일 밝혔다.
2024-03-22	Hanmi Pharmaceutical Company Limited	Results 한미약품 ‘ 아모잘탄패밀리 ’ 4상 결과, 국제학술지 ‘ AHJ ’ 등재 hanmi.co.kr ↗ 이는 Intensive 치료군에서 아모잘탄, 아모잘탄플러스 투여를 통한 우수한 혈압 조절이 좌심실 질량 감소에 유의한 효과를 나타낸다는 것을 입증한 결과다.
2023-11-03	Hanmi Pharmaceutical Company Limited	Results “한미 ‘아모잘탄패밀리, 로수젯, 클로잘탄’, 임상적 유용성 뚜렷” hanmi.co.kr ↗
2023-05-04	Hanmi Pharmaceutical Company Limited	Regulatory 한미, 저용량 이뇨제 붙인 고혈압 복합제 허가...라인업 지속 확장 hanmi.co.kr ↗ 한미약품은 최근 식품의약품안전처로부터 고혈압 치료 복합신약 ‘클로잘탄정 50/6.25mg’을 신규로 허가 받았으며, 오는 7월초 제품을 출시할 예정이라고 밝혔다.
2022-06-02	Hanmi Pharmaceutical Company Limited	Regulatory 한미, 고혈압 복합신약 라인업 확대...’클로잘탄’ 허가 획득 hanmi.co.kr ↗ 한미약품(대표이사 우종수·권세창)은 최근 식품의약품안전처로부터 ARB 계열 성분 ‘로사르탄(Losartan)’과 Thiazide-like 계열 이뇨제 성분 ‘클로르탈리돈(Chlorthalidone)을 결합한 2제 고혈압 치료 복합제 ‘클로잘탄정’ 2개 용량(50/12.5mg, 100/12.5mg)을 허가 받았다고 2일 밝혔다.
2018-05-23	Hanmi Pharmaceutical Company Limited	Results <보도자료> “임상적 효과 입증한 아모잘탄 패밀리, 용량 선택도 다양” hanmi.co.kr ↗
2017-11-07	Hanmi Pharmaceutical Company Limited	Results <보도자료> 한미약품, 대한고혈압학회서 ‘아모잘탄 패밀리’ 심포지엄 hanmi.co.kr ↗
2017-10-19	Hanmi Pharmaceutical Company Limited	Results <보도자료> 한미약품 ‘아모잘탄플러스’ 3상 결과, SCI급 국제학술지 등재 hanmi.co.kr ↗ 임상 결과, 아모잘탄플러스 투여군이 Amlodipine/Losartan 2제 요법 투여군과 비교하여 기저치 대비 8주 후 sitSBP를 평균 9.5mmHg 더 감소시키는 결과를 보였다.
2017-10-13	Hanmi Pharmaceutical Company Limited	Results <보도자료> 한미약품, 대한심장학회서 ‘아모잘탄 패밀리’ 심포지엄 열어 hanmi.co.kr ↗
2017-06-30	Hanmi Pharmaceutical Company Limited	Regulatory <보도자료> 한미, 고혈압치료 3제 복합신약 ‘아모잘탄플러스’ 허가 hanmi.co.kr ↗ 한미약품(대표이사 우종수·권세창, www.hanmi.co.kr)은 지난 29일 고혈압치료 3제 복합신약인 ‘아모잘탄플러스’의 시판허가를 식품의약품안전처로부터 받았다고 30일 밝혔다.

All press releases naming this drug 10 releases

Date	Issuer	Release
2025-06-13	Hanmi Pharmaceutical Company Limited	“고혈압 1차 치료의 새로운 길”…한미약품 ‘아모프렐’ 출격 준비 hanmi.co.kr ↗
2024-03-22	Hanmi Pharmaceutical Company Limited	한미약품 ‘ 아모잘탄패밀리 ’ 4상 결과, 국제학술지 ‘ AHJ ’ 등재 hanmi.co.kr ↗
2023-11-03	Hanmi Pharmaceutical Company Limited	“한미 ‘아모잘탄패밀리, 로수젯, 클로잘탄’, 임상적 유용성 뚜렷” hanmi.co.kr ↗
2023-05-04	Hanmi Pharmaceutical Company Limited	한미, 저용량 이뇨제 붙인 고혈압 복합제 허가...라인업 지속 확장 hanmi.co.kr ↗
2022-06-02	Hanmi Pharmaceutical Company Limited	한미, 고혈압 복합신약 라인업 확대...’클로잘탄’ 허가 획득 hanmi.co.kr ↗
2018-05-23	Hanmi Pharmaceutical Company Limited	<보도자료> “임상적 효과 입증한 아모잘탄 패밀리, 용량 선택도 다양” hanmi.co.kr ↗
2017-11-07	Hanmi Pharmaceutical Company Limited	<보도자료> 한미약품, 대한고혈압학회서 ‘아모잘탄 패밀리’ 심포지엄 hanmi.co.kr ↗
2017-10-19	Hanmi Pharmaceutical Company Limited	<보도자료> 한미약품 ‘아모잘탄플러스’ 3상 결과, SCI급 국제학술지 등재 hanmi.co.kr ↗
2017-10-13	Hanmi Pharmaceutical Company Limited	<보도자료> 한미약품, 대한심장학회서 ‘아모잘탄 패밀리’ 심포지엄 열어 hanmi.co.kr ↗
2017-06-30	Hanmi Pharmaceutical Company Limited	<보도자료> 한미, 고혈압치료 3제 복합신약 ‘아모잘탄플러스’ 허가 hanmi.co.kr ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 84 sources stand behind the page.

Field	Value	Cited text
Known as	chlorthalidone	“The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide,...” NCT04192110 ↗ 80 “Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together” NCT05077462 ↗ “Fixed-dose combination tablet containing valsartan 160 mg, amlodipine 10 mg, and chlorthalidone 25 mg.” NCT07116863 ↗ “Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300 ↗ “renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide” NCT00684489 ↗ “Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning” NCT01896661 ↗ “telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg” PMID 41717679 ↗ Feb 2026 “telmisartan/amlodipine/chlorthalidone 40/5/12.5 mg” NCT02620163 ↗ “amlodipine, Losartan, Chlorthalidone FDC” NCT02916602 ↗ “C52R2(Chlorthalidone) 25 mg tablet” NCT05077475 ↗ “chlorthalidone (Thalitone)” NCT00000620 ↗ Show 70 more sources
Known as	chlorthalidone (Thalitone)	“chlorthalidone (Thalitone)” NCT00000620 ↗
Known as	CTD	“We performed 12-hour urine collections in 7 patients taking 25 mg of chlorthalidone (CTD) and 10 patients taking 25 mg of hydrochlorothiazide (HCTZ).” PMID 40194294 ↗ Apr 2025 4 “chlorthalidone (CTD) is a thiazide-like diuretic used for treating hypertension and decreases serum K.” NCT05222191 ↗ “Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug” PMID 32663820 ↗ Jul 2020 “Chlorthalidone (CTD) may be superior to hydrochlorothiazide (HCTZ)” PMID 36067089 ↗ Sep 2022 “Chlorthalidone (CTD)” NCT02185417 ↗
Known as	HIGROTON 50	“Chlorthalidone (HIGROTON® 50)” NCT05090449 ↗
Known as	Hygroton (brand name for chlorthalidone)	“Hygroton (brand name for chlorthalidone)” NCT05411991 ↗
Modality	Other / unclassified	“Chlorthalidone is a thiazide-like diuretic” NCT00591773 ↗
Route	Oral	“chlorthalidone 25 mg, tablets, orally, once daily” NCT00591773 ↗